Cargando…

A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma

18F-fluorodeoxyglucose PET-CT may guide treatment decisions in patients with oesophageal adenocarcinoma (OAC). This study evaluated the added value of maximum standardised uptake value (SUVmax) to a novel DNA-damage immune response (DDIR) assay to improve pathological response prediction. The diagno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foley, Kieran G., Lavery, Anita, Napier, Eoin, Campbell, David, Eatock, Martin M., Kennedy, Richard D., Bradley, Kevin M., Turkington, Richard C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219719/ https://www.ncbi.nlm.nih.gov/pubmed/34158588 http://dx.doi.org/10.1038/s41598-021-92545-w

Ejemplares similares

Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer
por: Lavery, Anita, et al.
Publicado: (2021)

Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation
por: Gillham, Charles M, et al.
Publicado: (2007)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
por: Findlay, John M., et al.
Publicado: (2016)

The Evolution of Neo-Adjuvant Therapy in the Treatment of Oesophageal and Gastro-Oesophageal Junction Adenocarcinomas
por: Dermanis, Alexander A., et al.
Publicado: (2023)

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma
por: Turkington, Richard C, et al.
Publicado: (2019)

Identification of Novel Molecular Subgroups in Esophageal Adenocarcinoma to Predict Response to Neo-Adjuvant Therapies
por: Hoefnagel, Sanne J. M., et al.
Publicado: (2022)

Staging and Response Evaluation to Neo-Adjuvant Chemoradiation in Esophageal Cancers Using (18)FDG PET/CT with Standardized Protocol
por: Fatima, Nosheen, et al.
Publicado: (2019)

Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma
por: Blayney, Jaine K., et al.
Publicado: (2018)

Impact of regular enteral feeding via jejunostomy during neo-adjuvant chemotherapy on body composition in patients with oesophageal cancer
por: Mohamed, Imran M, et al.
Publicado: (2019)

Exercise efficacy and prescription during treatment for pancreatic ductal adenocarcinoma: a systematic review
por: O’Connor, Dominic, et al.
Publicado: (2021)

Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series
por: Brown, Malcolm, et al.
Publicado: (2023)

Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma
por: Jiang, William, et al.
Publicado: (2022)

Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening Approaches
por: McCabe, Niamh H., et al.
Publicado: (2022)

Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy
por: Fernanda Amary, M, et al.
Publicado: (2014)

[(18)F]FDG and [(18)F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer
por: Raccagni, Isabella, et al.
Publicado: (2018)

Accuracy of MRI for prediction of response to neo-adjuvant chemotherapy in triple negative breast cancer
por: Bansal, GJ, et al.
Publicado: (2015)

Cholethorax following Percutaneous Transhepatic Biliary Drainage
por: Turkington, Richard C, et al.
Publicado: (2007)

Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2018)

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
por: Di Cosimo, Serena, et al.
Publicado: (2020)

An immune surveillance model to monitor the response to neo-adjuvant chemotherapy treatment in breast cancer patients
por: Bernal-Estévez, David A, et al.
Publicado: (2015)

Low-dose immunotherapy as a potentiator to increase the response with neo-adjuvant chemotherapy in oral cancers
por: Rathinasamy, Narmadha, et al.
Publicado: (2023)

Apoptosis and autophagy markers predict survival in neoadjuvant treated oesophageal adenocarcinoma patients
por: El Mashed, Shereen, et al.
Publicado: (2022)

Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates
por: Couvreur, Karen, et al.
Publicado: (2018)

The challenges of using radiological ‘tumour response' as an outcome: lessons learned from neo-tango and artemis, two neo-adjuvant chemotherapy breast cancer trials
por: Hiller, Louise, et al.
Publicado: (2013)

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
por: Slagter, Astrid E., et al.
Publicado: (2018)

Author Correction: Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2018)

The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer
por: Chintamani, et al.
Publicado: (2007)

Discordant nodal staging identifies intermediate-risk group for overall survival in patients with cT3 oesophageal adenocarcinoma
por: Carder, Charles, et al.
Publicado: (2020)

Immune response to mutant neo-antigens: Cancer's lessons for aging
por: Geyer, Rory J, et al.
Publicado: (2013)

Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma
por: Chhabra, Arpit, et al.
Publicado: (2015)

Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma
por: Moore, Jonathan L., et al.
Publicado: (2023)

A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma
por: Eatock, M M, et al.
Publicado: (2000)

Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer
por: Sheri, A., et al.
Publicado: (2017)

Concordance Between Clinical and Pathological Response Assessment After Neo-Adjuvant Chemotherapy in Patients With Invasive Lobular Carcinoma
por: Shaikh, Aisha, et al.
Publicado: (2021)

Circulating Small EVs miRNAs as Predictors of Pathological Response to Neo-Adjuvant Therapy in Breast Cancer Patients
por: Baldasici, Oana, et al.
Publicado: (2022)

The Intensive Treatment of Kala-Azar by Neo-Stibosan
por: Napier, L. Everard, et al.
Publicado: (1928)

Adjuvant statin therapy for oesophageal adenocarcinoma: the STAT‐ROC feasibility study
por: Alexandre, L., et al.
Publicado: (2019)

Development and validation of a prognostic model incorporating texture analysis derived from standardised segmentation of PET in patients with oesophageal cancer
por: Foley, Kieran G, et al.
Publicado: (2017)

Colorectal Cancer in the Elderly Patient: The Role of Neo-adjuvant Therapy
por: Dodaro, Concetta Anna, et al.
Publicado: (2019)

The role of neo-adjuvant therapy in cholangiocarcinoma: A systematic review
por: Cremen, Sinead, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qlb0rrs06h1ilj7qbrt8c28pa1